|
18 Feb 2019 |
KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma (RCC)
|
|
15 Feb 2019 |
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma
|
|
15 Feb 2019 |
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer
|
|
14 Feb 2019 |
Innovent Announces First Patient Dosed in a Phase I Clinical Trial of an Anti-OX40 Antibody
|
|
13 Feb 2019 |
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and IMFINZI® (durvalumab) in Multiple Types of Advanced Non-Hodgkin Lymphoma
|
|
12 Feb 2019 |
Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts
|
|
12 Feb 2019 |
Active Biotech's partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study
|
|
12 Feb 2019 |
Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) Split Dosing Regimen
|
|
12 Feb 2019 |
Alpine Immune Sciences Announces First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program ALPN-101
|
|
12 Feb 2019 |
Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 30-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
|
|
12 Feb 2019 |
European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma
|
|
12 Feb 2019 |
FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma
|
|
11 Feb 2019 |
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
|
|
10 Feb 2019 |
One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium
|
|
07 Feb 2019 |
Antidote Therapeutics Announces Collaboration with National Cancer Institute to Develop ATI-1013, a Novel Nicotine-Binding Antibody, for Reducing Lung Cancer in High Risk Smokers
|
|
07 Feb 2019 |
Arch Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of AO-176, an Anti-CD47 Antibody with a Best-in-Class Profile
|
|
07 Feb 2019 |
Innovent Receives IND Approval of a Bispecific Antibody (IBI318) by the NMPA
|
|
06 Feb 2019 |
FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired throm
|
|
06 Feb 2019 |
MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
|
|
05 Feb 2019 |
US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897
|
|
05 Feb 2019 |
Genentech Submits Supplemental Biologics License Application to FDA for Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
|
|
05 Feb 2019 |
Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
|
|
05 Feb 2019 |
CHMP recommends EU approval of Roche's Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer
|
|
05 Feb 2019 |
Surface Oncology Retains Worldwide Rights for its First-in-Class Antibody Targeting IL-27, SRF388
|
|
04 Feb 2019 |
Chugai’s Hemlibra® Gains Positive CHMP Opinion in Severe Hemophilia A Without Inhibitors
|
